David-Alexandre C. Gros, MD

Charlotte Robinson

DocwireNews

Exciting advances in kidney xenotransplantation have made headlines of late. Most recently, it was announced that surgeons at Massachusetts General Hospital had completed a transplant of a genetically edited porcine kidney in January 2025—the fourth such procedure worldwide and the second at Mass General. The transplant recipient is one of two individuals currently living with a pig kidney.
As with the first-ever kidney xenotransplant, conducted at Mass General in March 2024, the patient is receiving the investigational therapeutic tegoprubart to help prevent rejection of the new organ. The drug was also used in the second-ever pig-to-human heart transplant.
Tegoprubart blocks the CD40 ligand (CD40L) pathway, which regulates immune cell communication and activation. Three global studies are evaluating the drug for the prevention of organ rejection in patients receiving kidney transplants, and it is also the subject of a separate investigator-sponsored trial for the prevention of islet transplant rejection in patients with type 1 diabetes.
To learn more about the history and potential of tegoprubart, Nephrology Times spoke with David-Alexandre C. Gros, MD, the CEO of Eledon Pharmaceuticals, the drug’s developer.

Cecilia Brown

FDA Grants Fast Track Designation to IBI363 for Squamous NSCLC

Immunotherapy in NSCLC

Kirk Huntsman

Rob Dillard

Revolutionizing Sleep Apnea Diagnostics With Home Sleep Testing Solutions

Sleep Disorders

CD40L Blocker Tegoprubart Playing Key Role in Xenotransplantation

Kidney Transplantation

Latest News

Eledon Pharmaceuticals CEO David-Alexandre Gros, MD, spoke about the role of CD40L blocker tegoprubart in transplantation.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe